Iron Chelation Therapy in Thalassemia Syndromes

Cianciulli, Paolo

doi:10.4084/mjhid.2009.0034

Cited by 11 publications

(11 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Oral iron chelators offer a convenient administration regimen overcoming the burden of subcutaneous infusions of DFO and potentially could improve patients 'compliance. Treating patients with tailored therapy regimes eventually lead to reduced ironrelated morbidity and mortality (6).…”

mentioning

confidence: 99%

Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients

Elalfy

Adly

Wali

et al. 2015

European J of Haematology

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients

Elalfy

Adly

Wali

et al. 2015

European J of Haematology

View full text Add to dashboard Cite

show abstract

“…DFO has been used to protect patients from toxic effects of iron overload, especially in cases of thalassemia and transfusion-dependent anemias (90). NAC was chosen over other reactive oxidants scavengers because of its strong efficiency to enter inside cells and less toxicity in comparison with other reactive oxidant scavengers.…”

Section: Discussionmentioning

confidence: 99%

Impact of Intravascular Hemolysis in Malaria on Liver Dysfunction

Dey¹,

Bindu

Goyal

et al. 2012

Journal of Biological Chemistry

View full text Add to dashboard Cite

“…Deferoxamin (DFO) merupakan salah satu terapi kelasi yang secara signifikan meningkatkan kualitas hidup dan angka harapan hidup sampai 10 tahun (Cianciulli, 2009). DFO diberikan secara parenteral dan infus dengan waktu yang cukup lama dan menimbulkan nyeri sehingga menurunkan kepatuhan pasien dalam melakukan pengobatan (Ibrahiem, 2013dan Poggiali, 2012.…”

Section: Angkaunclassified

“…Deferiprone (DFP) merupakan agen kelasi oral pertama yang diciptakan dan efektif mengikat kelebihan besi dan mengeluarkannya dari dalam tubuh sehingga dapat menggantikan peran DFO dalam mengatasi kelebihan besi tubuh (Jamuar dan Lai, 2012 (Cianciulli, 2009). Deferasirox (DFX) merupakan salah satu agen kelasi oral baru yang diminum hanya sekali sehari (Cianciulli, 2009). Studi menyatakan pasien lebih nyaman mengkonsumsi DFX daripada DFO (Poggiali et al, 2012).…”

Section: Angkaunclassified

Hubungan Kepatuhan Terapi Kelasi Dengan Kadar Feritin Serum Pada Pasien Thalasemia B Mayorpada Anak Di Rsam Provinsi Lampung

2021

View full text Add to dashboard Cite

RELATIONSHIP OF COMPLIANCE WITH KELSI THERAPY WITH SERUM FERITIN LEVELS IN THALASSEMIA β MAYOR PATIENTS IN CHILDREN AT BANDAR LAMPUNG HOSPITAL Background: Thalassemia is a heterogeneous group of hereditary anemia caused by mutations in hemoglobin synthesis (Cunningham et al., 2009). In the world, thalassemia annually reaches 1 in 100,000 people. The incidence of thalassemia in the world is based on data from the World Health Organization or the World Health OrganizationPurpose To determine the relationship between chelation therapy provision and serum ferritin levels in Thalassemia B Mayor patients in Dr. Hi Abdul Moeloek, Lampung Province in 2019.Aim: To find out the relationship between the adherence to iron therapy with serum ferritin levels at RSAM in 2019.Methods: This research is quantitative with the observational analytic method with a cross-sectional approach. The total population was 115 patients. A sample of 60 patients thalassemia β mayor. This research was conducted from Feb 2020 to completion. Analysis through univariate analysis.Results: the relationship of compliance with kelasi therapy with serum feritin levels in thalasemia β mayor patients at rsam hospital 2019, 34 respondents who obeyed chelation therapy, as many as 21 respondents (61.8%) had no risk ferritin levels (≤1000), of the 36 respondents who did not comply with chelation therapy, as many as 6 respondents (23.1%) had levels ferritin No Risk (≤1000) The results of the analysis also obtained an OR value of 5.38 (95% CI 1.7-16.9), which means that respondents who are adherent to iron therapy are at risk of having ferritin levels at risk (≥ = 1000) 5.38 times greater than who do not adhere to iron therapy.Conclusion: It is known that there is a relationship between adherence to iron therapy and serum ferritin levels at rsam hospital in 2019. Keywords: Thalassemia, Iron Therapy, Ferritin LevelsINTISARI: HUBUNGAN KEPATUHAN TERAPI KELASI DENGAN KADAR FERITIN SERUM PADA PASIEN THALASEMIA β MAYOR PADA ANAK DI RSAM BANDAR LAMPUNG Latar Belakang : Thalasemia merupakan salah satu kelompok heterogen anemia herediter yang disebabkan oleh mutasi pada sintesis hemoglobin (Cunningham et al., 2009). Di dunia, insiden thalasemia setiap tahunnya diperkirakan mencapai 1 dari 100.000 orang. Angka kejadian penyakit thalasemia di dunia berdasarkan data dari Badan Organisasi Kesehatan Dunia atau World Health OrganizationTujuan Mengetahui hubungan kepatuhan terapi kelasi dengan kadar feritin serum pada pasien Thalasemia B Mayor Di RSUD Dr. Hi Abdul Moeloek Provinsi Lampung Tahun 2019Metode Penelitian : Penelitian ini adalah kuantitatif dengan metode analitik observasional dengan pendekatan cross sectional. Jumlah populasi 115 pasien. Sampel 60 pasien dengan diagnosis thalassemia β mayor. Peneltian ini dilakukan pada bulan februari 2020 sampai dengan selesai. Analisa melalui analisa bivariat. Hasil : hubungan kepatuhan terapi kelasi dengan kadar ferritin serum pada pasien thalsemia β mayor di RSAM bandar lampung tahun 2019 34 responden yang patuh dalam terhadap terapi kelasi, sebanyak 21 responden (61,8%) memiliki kadar ferritin Tidak Beresiko (≤1000), dari 36 responden yang tidak patuh dalam terhadap terapi kelasi, sebanyak 6 responden (23,1%) memiliki kadar ferritin Tidak Beresiko (≤1000. Hasil analisis diperoleh pula nilai OR 5,38 (95% CI 1,7-16,9) yang berarti bahwa responden yang patuh dalam terhadap terapi kelasi, berisiko memiliki kadar feritin beresiko (≥=1000) 5,38 kali lebih besar dibandingkan dengan yang tidak patuh dalam terhadap terapi kelasi.Kesimpulan : Diketahui terdapat hubungan kepatuhan terapi kelasi dengan kadar ferritin serum di RSAM Bandar Lampung tahun 2020 Kata kunci : Thalasemia, Terapi Kelasi, Feritin Serum

show abstract

Iron Chelation Therapy in Thalassemia Syndromes

Cited by 11 publications

References 33 publications

Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients

Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients

Impact of Intravascular Hemolysis in Malaria on Liver Dysfunction

Hubungan Kepatuhan Terapi Kelasi Dengan Kadar Feritin Serum Pada Pasien Thalasemia B Mayorpada Anak Di Rsam Provinsi Lampung

Contact Info

Product

Resources

About